Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QT-019C in Refractory Primary Immune Thrombocytopenia
NCT07416032Phase 1Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/BCMA CAR T-cells in immune thrombocytopenia (ITP). Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events at 28 days. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07416032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416032.